Search results for "Raltegravir"

showing 8 items of 8 documents

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/…

2017

Background: Nucleos(t)ide reverse transcriptase inhibitors (NRTI) toxicity may represent a threat for long-term success of combined antiretroviral therapy. Some studies have suggested a possible improvement of NRTI-related toxicity after switching to NRTI-sparing regimens. Objectives: We aimed to explore the efficacy and tolerability of switching to darunavir/ritonavir (DRV/r) plus raltegravir (RAL) while having a viral load (VL) ≤50 copies/mL in the clinical setting. Study design: Treatment-experienced HIV 1-infected patients enrolled in the ICONA Foundation Study cohort were included if they switched their current regimen to DRV/r + RAL with a HIV-RNA ≤50 copies/mL. Different defin…

0301 basic medicineMaleHIV InfectionsAntiretroviral therapy; Darunavir/ritonavir; Efficacy; NRTI-sparing regimen; Raltegravir; Tolerability; Microbiology (medical); Infectious DiseasesAntiretroviral therapy; Darunavir/ritonavir; Efficacy; NRTI-sparing regimen; Raltegravir; Tolerability; Adult; Anti-HIV Agents; Cohort Studies; Darunavir; Drug Therapy Combination; Female; HIV Infections; HIV-1; Humans; Italy; Male; Middle Aged; RNA Viral; Raltegravir Potassium; Ritonavir; Viral LoadGastroenterologyCohort StudiesAntiretroviral therapy; Darunavir/ritonavir; Efficacy; NRTI-sparing regimen; Raltegravir; Tolerability0302 clinical medicineMedicineNRTI-sparing regimen030212 general & internal medicineViralDarunavireducation.field_of_studyLamivudineGeneral MedicineMiddle AgedViral LoadTolerabilityAntiretroviral therapyInfectious DiseasesTolerabilityItalyCombinationRNA ViralDrug Therapy CombinationFemaleViral loadmedicine.drugAdultMicrobiology (medical)medicine.medical_specialtyEfficacyAnti-HIV Agents030106 microbiologyPopulationDarunavir/ritonavir; Raltegravir; Efficacy; Tolerability; Antiretroviral therapy; NRTI-sparing regimenSettore MED/17 - MALATTIE INFETTIVELower riskNO03 medical and health sciencesDrug TherapyInternal medicineRaltegravir PotassiumHumanseducationDarunavirRitonavirbusiness.industryDarunavir/ritonavirRaltegravirRaltegravirHIV-1RNARitonavirbusinessAntiretroviral therapy; Darunavir/ritonavir; Efficacy; NRTI-sparing regimen; Raltegravir; Tolerability;
researchProduct

Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort

2019

AbstractObjectivesTo evaluate the incidence and risk factors for liver enzyme elevations (LEE) in patients initiating first-line ART in the ICONA prospective observational cohort, between June 2009 and December 2017.Patients and methodsIn total, 6575 ART-naive patients were selected, initiating two NRTIs with the third drug being a boosted PI (n=2436; 37.0%), an NNRTI (n=2384; 36.3%) or an integrase strand transfer inhibitor (INSTI) (n=1755; 26.7%). HBV surface antigen and HCV RNA were detected in 3.9% and 5.8% of the study population. Inverse probability weighted Cox regression analysis was used to calculate the HRs, according to first-line regimen, for LEE, defined as ALT or AST increases…

0301 basic medicineMaleIntegrase inhibitorHepatitis B Surface AntigenHIV Infections0302 clinical medicineRisk Factorshivh epatitis c rna surface antigens follow-up homosexuality integrase inhibitors hepatitis b virus hepatitis b virus measurement hiv infections hepatotoxicity hepatitis c virus coinfection nucleoside reverse transcriptase inhibitors non-nucleoside reverse transcriptase inhibitors cox proportional hazards models baseline value liver enzyme raltegravirPharmacology (medical)HIV Infection030212 general & internal medicineProspective StudiesProspective cohort studyCoinfectionIncidence (epidemiology)Liver DiseaseIncidenceLiver Diseasesvirus diseasesHepatitis CMiddle AgedHepatitis CReverse Transcriptase InhibitorInfectious DiseasesCohortCoinfectionPopulation studyRegression AnalysisReverse Transcriptase InhibitorsFemalemedicine.drugHumanMicrobiology (medical)Adultmedicine.medical_specialtyAnti-HIV AgentsRegression AnalysiNO03 medical and health sciencesInternal medicinemedicineHumansHIV Integrase InhibitorsHIV Protease InhibitorPharmacologyHepatitis B Surface Antigensbusiness.industryAnti-HIV AgentHIV ARTHIV Protease Inhibitorsmedicine.diseaseRaltegravir030112 virologyHIV Integrase InhibitorProspective StudieHIV-1businessAdult Anti-HIV Agents Coinfection Female Hepatitis B Surface Antigens Hepatitis C HIV Infections HIV Integrase Inhibitors HIV Protease Inhibitors HIV-1 Humans Incidence Liver Diseases Male Middle Aged Prospective Studies Regression Analysis Reverse Transcriptase Inhibitors Risk Factors
researchProduct

Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir.

2015

ABSTRACT Raltegravir pharmacokinetics was studied in 20 patients included in the ANRS HC30 QUADRIH Study before and after addition of anti-hepatitis C virus (anti-HCV) quadritherapy, including pegylated-interferon–ribavirin and asunaprevir plus daclatasvir. Raltegravir pharmacokinetic parameters remained unchanged whether administered on or off anti-HCV therapy. In addition, concentrations of raltegravir, asunaprevir, and daclatasvir were not affected by liver cirrhosis. These data suggest that in human immunodeficiency virus (HIV)-HCV-coinfected patients, whether cirrhotic or not, asunaprevir and daclatasvir could be administered safely with raltegravir.

AdultLiver CirrhosisMaleDaclatasvirPyrrolidinesAlpha interferonHIV InfectionsHepacivirusPharmacologyAntiviral AgentsRaltegravir PotassiumPolyethylene Glycolschemistry.chemical_compoundPharmacokineticsRaltegravir PotassiumRibavirinMedicineHumansPharmacology (medical)PharmacologySulfonamidesbusiness.industryCoinfectionRibavirinImidazolesvirus diseasesInterferon-alphaValineHepatitis CHepatitis C ChronicMiddle AgedRaltegravirmedicine.diseaseIsoquinolinesdigestive system diseasesRecombinant ProteinsInfectious DiseaseschemistryLiverHIV-1AsunaprevirDrug Therapy CombinationFemaleCarbamatesbusinessmedicine.drugAntimicrobial agents and chemotherapy
researchProduct

Liver Fat, Adipose Tissue, and Body Composition Changes After Switching from a Protease Inhibitor or Efavirenz to Raltegravir.

2021

Integrase inhibitors appear to increase body weight, but paradoxically some data indicate that raltegravir (RAL) may decrease liver fat. Our objective was to study the effects of switching from a protease inhibitor (PI) or efavirenz (EFV) to RAL on liver fat, body composition, and metabolic parameters among people living with HIV (PLWH) with high risk for nonalcoholic fatty liver disease (NAFLD). We randomized overweight PLWH with signs of metabolic syndrome to switch a PI or EFV to RAL (

Cyclopropanesmedicine.medical_specialtyanimal structuresEfavirenzIntegrase inhibitorAdipose tissueHIV Infections03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAdipocyteInternal medicineRaltegravir PotassiumNonalcoholic fatty liver diseasemedicineHumansProtease inhibitor (pharmacology)Protease Inhibitors030212 general & internal medicinebusiness.industryPublic Health Environmental and Occupational Healthmedicine.diseaseRaltegravir3. Good healthBenzoxazinesInfectious DiseasesEndocrinologychemistryAdipose TissueLiverAlkynesBody Composition030211 gastroenterology & hepatologymedicine.symptombusinessWeight gainmedicine.drugAIDS patient care and STDs
researchProduct

Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors

2020

Abstract Objectives This study evaluated the emergence of mutations associated with integrase strand transfer inhibitors (INSTI) resistance (INSTI-RMs) and the integrase evolution in human immunodeficiency virus type 1 (HIV-1) infected patients treated with this drug class. Methods The emergence of INSTI-RMs and integrase evolution (estimated as genetic distance between integrase sequences under INSTI treatment and before INSTI treatment) were evaluated in 107 INSTI-naive patients (19 drug-naive and 88 drug-experienced) with two plasma genotypic resistance tests: one before INSTI treatment and one under INSTI treatment. A logistic regression analysis was performed to evaluate factors associ…

Male0301 basic medicineIntegrase inhibitorHIV InfectionsHIV IntegraseQuinolonesPiperazineschemistry.chemical_compound0302 clinical medicineHIV-1 integrase resistanceImmunology and Allergy030212 general & internal medicineIntegrase inhibitorSubtype.genetic distancebiologyElvitegravirMiddle AgedQR1-502Integraseintegrase inhibitorsDolutegravirHiv 1 integraseFemaleHeterocyclic Compounds 3-Ringmedicine.drugAdultMicrobiology (medical)Settore MED/17 - Malattie InfettiveGenotypePyridones030106 microbiologyImmunologyMicrobiologysubtypeEvolution Molecular03 medical and health sciencesRaltegravir PotassiumDrug Resistance ViralOxazinesmedicineHumansIn patientHIV Integrase InhibitorsPolymorphismbusiness.industryHIV-1 integrase resistance; genetic distance; integrase inhibitors; polymorphisms; subtypeRaltegravirVirologyLogistic ModelschemistryMutationHIV-1Genotypic resistancebiology.proteinpolymorphismsbusinessJournal of Global Antimicrobial Resistance
researchProduct

High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Geno…

2015

BACKGROUND Few direct anti-hepatitis C virus (HCV) agents have been studied in difficult-to-treat null responder and cirrhotic human immunodeficiency virus (HIV)-coinfected patients. Daclatasvir and asunaprevir combined with pegylated interferon/ribavirin (peg-IFN/RBV) have shown promising results in HCV-monoinfected patients. METHODS An open-label, single-arm, phase 2 study was conducted in HIV/HCV genotype 1/4-coinfected patients who were null responders to prior peg-IFN/RBV standard therapy and on a raltegravir-based regimen with HIV RNA <400 copies/mL. They received a 4-week lead-in phase with peg-IFN/RBV, followed by 24 weeks of asunaprevir (100 mg twice daily), daclatasvir (60 mg once…

MaleMicrobiology (medical)medicine.medical_specialtyPyrrolidinesDaclatasvir[SDV]Life Sciences [q-bio]PopulationHIV InfectionsHepacivirusAntiviral AgentsGastroenterologychemistry.chemical_compoundPegylated interferonInternal medicinemedicineHumansdaclatasvireducationasunaprevireducation.field_of_study[ SDV ] Life Sciences [q-bio]Coinfectionbusiness.industryRibavirincirrhosisImidazolesvirus diseasesHIVValineHepatitis C ChronicMiddle AgedRaltegravirmedicine.disease3. Good healthRegimenTreatment OutcomeInfectious DiseaseschemistryImmunologyHCVCoinfectionAsunaprevirFemaleCarbamatesbusinessmedicine.drug
researchProduct

Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz.

2014

Objectives Growing evidence associates the non-nucleoside reverse transcriptase inhibitor efavirenz with several adverse events. Newer antiretrovirals, such as the integrase inhibitor raltegravir, the non-nucleoside reverse transcriptase inhibitor rilpivirine and the protease inhibitor darunavir, claim to have a better toxicological profile than efavirenz while producing similar levels of efficacy and virological suppression. The objective of this study was to determine the in vitro toxicological profile of these three new antiretrovirals by evaluating their effects on the mitochondrial and cellular parameters altered by efavirenz in hepatocytes and neurons. Methods Hep3B cells and primary …

Microbiology (medical)CyclopropanesEfavirenzAnti-HIV AgentsIntegrase inhibitorBiologyMitochondrionPharmacologychemistry.chemical_compoundCell Line TumorRaltegravir PotassiumDrug Resistance ViralNitrilesmedicineAnimalsHumansPharmacology (medical)DarunavirCells CulturedDarunavirPharmacologyNeuronsSulfonamidesReverse-transcriptase inhibitorRilpivirinemedicine.diseaseRaltegravirPyrrolidinonesBenzoxazinesMitochondriaRatsMitochondrial toxicityInfectious DiseasesPyrimidineschemistryRilpivirineAlkynesHepatocytesReverse Transcriptase Inhibitorsmedicine.drugThe Journal of antimicrobial chemotherapy
researchProduct

Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection.

2008

HIV-infected patients have a higher risk of developing cutaneous reactions than the general population, which has a significant impact on patients' current and future care options. The severity of cutaneous adverse reactions varies greatly, and some may be difficult to manage. HIV-infected patients just at the beginning of antiretroviral treatment can frequently show a wide variety of adverse drug effects such as drug rashes, hyperpigmentation, hair loss, hypersensitivity reactions, injection site reaction, urticarial reaction, erythema multiforme, toxic epidermal necrolysis or Stevens-Johnson syndrome. The early detection and treatment of cutaneous adverse drug reactions, plus identificati…

PharmacologyMicrobiology (medical)Enfuvirtidebusiness.industryAnti-HIV AgentsEtravirineIntegrase inhibitorHIV Infectionsmedicine.diseaseRaltegravirSkin Diseaseschemistry.chemical_compoundInfectious DiseaseschemistryInjection site reactionImmunologymedicineHumansPharmacology (medical)Protease inhibitor (pharmacology)businessTipranavirmedicine.drugMaravirocThe Journal of antimicrobial chemotherapy
researchProduct